Atypical Hemolytic Uremic Syndrome (aHUS)

This is a rare condition that affects the kidneys. It happens when the body's immune system attacks red blood cells, leading to kidney failure. It's different from the more common type of Hemolytic Uremic Syndrome (HUS) which is often caused by certain bacteria. People with aHUS usually don't have the typical stomach bug symptoms first. It requires careful medical care.

Condition

What people with Atypical Hemolytic Uremic Syndrome (aHUS) report

Every report comes from a Lived member, sent anonymously.

Have you tried Ultomiris (Ravulizumab) for Atypical Hemolytic Uremic Syndrome (aHUS)?

NameHow it went

About Atypical Hemolytic Uremic Syndrome (aHUS)

What It Is

Atypical hemolytic uremic syndrome (aHUS) is a very rare disease in which part of the immune system, called the complement system, attacks the lining of small blood vessels. Tiny clots form inside those vessels, most often in the kidneys. The result is a combination of three problems: red blood cells break apart as they squeeze past the clots (hemolytic anemia), platelets are used up in the clots (a low platelet count), and the kidneys are injured, sometimes suddenly and severely. The anemia can cause tiredness, pale skin, shortness of breath and a fast heartbeat, and a low platelet count can cause easy bruising. Kidney injury may show up as swelling, passing less urine than usual and high blood pressure. Because the clots can form anywhere, aHUS sometimes also affects the brain, heart, gut, lungs or eyes. It can begin at any age, from infancy to later adulthood. The word atypical separates it from typical hemolytic uremic syndrome, which is more common and follows an infection with toxin-producing E. coli bacteria, usually with diarrhea and usually in young children. The two look alike in blood tests but have different causes, treatments and outlooks. Doctors increasingly call aHUS complement-mediated HUS, which names what drives it.

Causes & Risk Factors

The complement system is a set of blood proteins that helps destroy germs. It is normally held in check by regulating proteins that stop it from damaging the body's own cells. In aHUS, that control fails. In about 60 to 70 percent of people, a cause can be found: an inherited or new change in one of the genes that make complement proteins (the gene for factor H, CFH, is the most common), or, less often, antibodies that block factor H. Antibody-related aHUS is seen mostly in children. A gene change usually raises risk rather than causing disease on its own. Many people who carry one never become ill, which is why relatives can share the same change without symptoms. An episode is often set off by a second event that stresses blood vessels or activates complement, such as an infection, pregnancy or the weeks after delivery, certain medicines (including some cancer drugs), an organ transplant or cancer. Some people have no identifiable gene change or trigger. Most cases appear in people with no family history; fewer than 1 in 5 run in families. A negative family history therefore does not rule aHUS out, and a positive one does not mean a relative will develop it.

How It's Diagnosed

There is no single test that confirms aHUS. Doctors first confirm the pattern of clotting in small vessels, known as thrombotic microangiopathy, and then rule out the other conditions that produce the same pattern. Blood tests show whether red cells are being destroyed and platelets consumed: a low hemoglobin and platelet count, a high lactate dehydrogenase (LDH, an enzyme released from damaged cells), a low haptoglobin (a protein used up when red cells break down), and fragmented red cells called schistocytes on a blood smear. Creatinine (a waste product that rises in the blood when the kidneys filter less well) and urine tests measure how much the kidneys are affected. Two look-alikes must be excluded quickly because they are treated differently. A stool test checks for toxin-producing E. coli, the cause of typical HUS. A blood test of ADAMTS13 activity checks for thrombotic thrombocytopenic purpura (TTP), a related clotting disorder; activity above 10 percent points away from TTP. Doctors also look for other causes such as pregnancy complications, medicines, autoimmune disease, severe high blood pressure and, in young children, rare problems with vitamin B12 processing. Genetic testing and tests for factor H antibodies help explain the cause and guide long-term decisions, but results can take weeks and a negative genetic test does not rule out aHUS. Blood levels of the complement protein C3 are low in only a minority of people. A kidney biopsy is sometimes done, particularly after a kidney transplant, but is not required for diagnosis.

Treatment Options

Treatment aims to stop the clotting process quickly, before it causes permanent kidney or other organ damage, and then to keep it from returning. The main treatment is a complement inhibitor, a lab-made antibody that blocks a complement protein called C5 and so shuts off the attack on blood vessel walls. Two are approved in the US for aHUS: eculizumab (Soliris) and ravulizumab (Ultomiris), which is approved from 1 month of age. Both are given as infusions into a vein. After starting doses, eculizumab is usually given every 2 weeks in adults, while ravulizumab lasts longer and is given every 4 or 8 weeks depending on body weight. In studies, eculizumab stopped active clotting, raised platelet counts and improved kidney function over time in many people. Delays in starting effective treatment are linked to worse outcomes, which is why doctors often begin it before every test result is back. Blocking complement weakens defense against certain bacteria, especially meningococcus, which causes meningitis and bloodstream infection. People need meningococcal vaccines, ideally at least 2 weeks before the first dose; when treatment cannot wait, antibiotics are given until the vaccines take effect. Vaccination lowers but does not remove the risk, so people receive a Patient Safety Card to carry during treatment and for 3 months after stopping eculizumab or 8 months after stopping ravulizumab. If a complement inhibitor is not available right away, plasma exchange or plasma infusions may be used as a bridge. They can temporarily improve blood counts, and plasma exchange can remove factor H antibodies, but they do not reliably keep the disease in remission or restore kidney function. Supportive care matters too: controlling blood pressure, managing fluids and salts, adjusting medicines that strain the kidneys, and dialysis if the kidneys fail.

What to Expect

The course of aHUS varies a great deal. Some people have a single episode, while others have repeated flares over years, often set off by infections or pregnancy. Before complement inhibitors were available, about half of people developed kidney failure; with timely treatment, many now regain much or all of their kidney function, although some are left with lasting kidney damage and high blood pressure. Once the disease is controlled, daily life on treatment revolves around regular infusions, routine blood and urine tests to catch early signs of activity, blood pressure checks and staying up to date on vaccines. How long to stay on a complement inhibitor is an individual decision with no settled answer. In studies, up to about 1 in 3 people relapsed after stopping, and the risk is higher with certain gene changes, such as those in CFH. When stopping is tried, it is a planned, shared decision with close monitoring for at least 12 weeks after eculizumab or at least 12 months after ravulizumab, and a plan to restart quickly if the disease returns. Pregnancy can trigger aHUS or a relapse, most often late in pregnancy or after delivery, so anyone with aHUS who is considering pregnancy benefits from planning with their specialists. For people with kidney failure, a kidney transplant is possible, but without prevention aHUS returns in the new kidney in half or more of cases. Transplant teams use genetic results to judge that risk, often give a complement inhibitor to prevent recurrence, and generally avoid kidney donation from blood relatives, who may carry the same gene change.

When to Seek Help

If you have aHUS, contact your care team promptly if you notice signs that the disease may be returning: passing much less urine, new swelling of the legs or face, unusually high home blood pressure readings, unexplained bruising or bleeding, or growing tiredness, paleness or breathlessness. Let them know right away about a missed infusion, an infection, or a pregnancy. Get emergency care for seizures, chest pain, sudden confusion or severe shortness of breath, which can mean clotting is affecting the brain, heart or lungs. If you take, or recently stopped, eculizumab or ravulizumab, seek emergency medical care right away for fever, especially with a rash or a fast heartbeat, or for headache with a stiff neck, nausea or vomiting, confusion, or eyes that are sensitive to light, since meningococcal infection can become life-threatening very quickly. Show your Patient Safety Card.

Questions to Ask Your Doctor

  1. 1.What tests ruled out typical HUS, TTP and other causes in my case, and are any results still pending?
  2. 2.Did genetic or antibody testing find a cause, and what does that mean for my risk of relapse and for my relatives?
  3. 3.Which complement inhibitor and infusion schedule suit me, and how will we know it is working?
  4. 4.Is there a point when stopping treatment would be reasonable, and how would we watch for a relapse?
  5. 5.How should I plan for a future pregnancy or a kidney transplant?

Last reviewed • Oct 2026

Educational content, not medical advice.